Overview: HCV RNA Genotype TestIntroduction: The HCV RNA Genotype Test identifies hepatitis C virus genotypes to guide treatment, preventing liver complications. Aligned with 2023 AASLD guidelines, it uses PCR for high specificity, aiding in infectious disease screening. This test is critical for tailoring antiviral therapy, optimizing treatment outcomes, and improving outcomes in virology for patients with chronic hepatitis C, ensuring effective management to prevent progression to cirrhosis.
Other Names: HCV Genotype Assay, Hepatitis C Typing Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: HCV genotyping began in the 1990s with PCR development. Genotyping assays improved in the 2000s, enhancing treatment personalization with DAAs.
Purpose: Identifies HCV genotypes, guides antiviral therapy, and monitors genotypes in patients to prevent liver complications.
Test Parameters: 1. HCV Genotype
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report history of hepatitis C, treatment status, or symptoms like fatigue, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, liver pain, or history of chronic hepatitis C. Include current medications, especially DAAs, and treatment history.
Consent: Written consent required, detailing the tests purpose, treatment implications, and potential need for tailored antiviral therapy.
Procedural Considerations: Uses PCR to identify HCV genotypes (e.g., 1a, 1b, 2, 3). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, essential for DAA therapy planning.
Factors Affecting Result Accuracy: Poor RNA quality, low viral load, or contamination can affect results. Mixed genotypes may complicate interpretation.
Clinical Significance: Identified genotypes (e.g., genotype 1) guide DAA selection, improving treatment efficacy. Non-genotype 1 infections may require different regimens.
Specialist Consultation: Consult a hepatologist for result interpretation and antiviral therapy planning.
Additional Supporting Tests: HCV RNA, anti-HCV, or liver function tests to confirm infection and guide therapy.
Test Limitations: Low viral loads may limit genotyping. Mixed infections may require additional testing for accurate results.
References: AASLD Hepatitis C Guidelines, 2023; Hepatology, Ghany MG, 2022.
